Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Stem Cell Processing topic
No spam. Unsubscribe anytime.
Committee approves amended bill to allow in-state processing of certain stem-cell therapies, with fertility groups urging clarification
Summary
Lawmakers unanimously passed a substitute to let Georgia-based entities process umbilical-cord and placental-derived tissues for stem-cell therapies while excluding material derived from aborted fetuses; fertility advocates warned the bill’s language could unintentionally affect IVF and embryo-related care and asked for clearer definitions.
The Senate Health and Human Services Committee voted unanimously to approve an amended substitute of House Bill 1275, which would allow Georgia-based processing and limited manufacturing of certain stem-cell products derived from donated umbilical cords and placental tissue.
Representative Newton, the bill’s author, said the measure would shorten supply chains for treatments used in sports medicine, orthopedics and wound care, and would let Georgia producers process donated tissue locally rather than relying on out-of-state facilities. The bill expressly disclaims use of tissue "derived from aborted fetuses" and includes testing and sterility requirements.
Fadi Al Khatib, director at 0.1 Therapeutics (a firm processing such materials in Florida), described a three-stage sterility and hepatitis-testing regimen his company uses and said FDA standards apply to processing and testing. "We do three different rounds of sterility testing...to make sure the product is safe for our clients," he told the committee.
Lynn Goldman, president of the Georgia Fertility Network, urged the committee to remove or clarify the term "embryo" and asked for narrower language to avoid unintended consequences for IVF and embryo-related procedures. She said the bill’s broad definitions could create uncertainty for fertility providers and researchers and recommended explicit exemptions to preserve current IVF protections.
The author proposed two drafting corrections in response — removing a line and omitting one accreditor reference at counsel’s request — which the committee accepted. The amended substitute passed unanimously; the sponsor said the bill does not aim to change federally compliant research and that federal IRB- or institutional-review-oversight processes remain unaffected.
Committee members asked staff to confirm cross-references to last year’s legislation (Senate Bill 72 / House Bill 70) and to ensure accreditation and sourcing language matched stakeholders’ expectations. The committee recorded the bill as passed and assigned Senator Brass to carry it forward.
